ludovic Martinet

head of Team 13

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ludovic Martinet is the head of Team 13 at the Cancer Research Center of Toulouse, France. His research primarily focuses on multiple myeloma, including studies on GPRC5D-targeting therapies, the genetic factors influencing T-cell functions, and the prognostic implications of genetic lesions. His recent works explore the immune dysregulation in cancer and the role of tumor cell interactions in immunotherapy resistance.

Articles (12)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (11)

Sally-Ann Pearson

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

Isabelle Bernard

INSERM U1291, Infinity

FRANCE

View details

Yenkel Grinberg-Bleyer

FRANCE

View details

Frederic Deschaseaux

FRANCE

View details

Anne L Astier

FRANCE

View details

Sukhvinder Sidhu

Global Head of Pharmacology - Oncology

Sanofi-Aventis Recherche et Developpement Vitry-sur-Seine Alfortville

FRANCE

View details

Jean-Luc Teillaud

INSERM

FRANCE

View details

bettina couderc

Université Paul Sabatier

FRANCE

View details

Mika Casey

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

Olivier JOFFRE

Lab head

FRANCE

View details

Mark Smyth

Senior Scientist/Head, Immunology in Cancer & Infection Laboratory

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ludovic Martinet

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Impact of the Multiple Sclerosis-Associated Genetic Variant <i>CD226</i> Gly307Ser on Human CD8 T-Cell Functions

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

RAS/RAF landscape in monoclonal plasma cell conditions.

TCR-independent CD137 (4-1BB) signaling promotes CD8<sup>+</sup>-exhausted T cell proliferation and terminal differentiation.

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth.

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8<sup>+</sup> T Cells

Cancer immunoediting and immune dysregulation in multiple myeloma

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8<sup>+</sup> T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma.

Collaborators (11)

Sally-Ann Pearson

Isabelle Bernard

Yenkel Grinberg-Bleyer

Frederic Deschaseaux

Anne L Astier

Sukhvinder Sidhu

Jean-Luc Teillaud

bettina couderc

Mika Casey

Olivier JOFFRE

Mark Smyth

Make your next move.